https://infocrc.it/global-braf-testing-practices-in-metastatic-colorectal-cancer/ 2021-03-04T11:03:57+00:00 https://infocrc.it/wp-content/uploads/2021/03/4.jpg https://infocrc.it/phase-ii-study-of-ipilimumab-nivolumab-and-panitumumab-in-patients-with-kras-nras-braf-wild-type-wt-microsatellite-stable-mss-metastatic-colorectal-cancer-mcrc/ 2021-03-04T15:46:06+00:00 https://infocrc.it/wp-content/uploads/2021/03/2.jpg https://infocrc.it/real-world-data-on-overall-survival-associated-with-biweekly-versus-weekly-cetuximab-among-metastatic-colorectal-cancer-mcrc-patients-in-the-united-states/ 2021-03-05T07:44:40+00:00 https://infocrc.it/wp-content/uploads/2021/03/1.jpg https://infocrc.it/utility-of-circulating-tumor-dna-in-the-clinical-management-of-patients-with-brafv600e-metastatic-colorectal-cancer/ 2021-03-05T07:46:17+00:00 https://infocrc.it/wp-content/uploads/2021/03/2.jpg https://infocrc.it/overall-survival-based-on-msi-and-braf-mutation-status-for-stage-ii-iii-colorectal-cancer/ 2021-03-05T07:47:31+00:00 https://infocrc.it/wp-content/uploads/2021/03/3.jpg https://infocrc.it/is-antiangiogenic-therapy-necessary-for-patients-with-metastatic-colorectal-cancer-mcrc-and-mutation-in-the-braf-gene-results-of-the-systematic-review-and-meta-analysis/ 2021-03-05T07:48:08+00:00 https://infocrc.it/wp-content/uploads/2021/03/1.jpg https://infocrc.it/encorafenib-plus-cetuximab-as-a-new-standard-of-care-for-previously-treated-braf-v600e-mutant-metastatic-colorectal-cancer-updated-survival-results-and-subgroup-analyses-from-the-beacon-study/ 2021-03-05T07:48:41+00:00 https://infocrc.it/wp-content/uploads/2021/03/4.jpg https://infocrc.it/safety-analysis-of-the-randomized-phase-ii-study-of-folfoxiri-plus-cetuximab-versus-folfoxiri-plus-bevacizumab-as-the-first-line-treatment-in-metastatic-colorectal-cancer-with-ras-wild-type-tumors-th/ 2021-03-05T07:49:50+00:00 https://infocrc.it/wp-content/uploads/2021/03/3.jpg https://infocrc.it/paradigm-study-a-multicenter-randomized-phase-iii-study-of-mfolfox6-plus-panitumumab-or-bevacizumab-as-first-line-treatment-in-patients-with-ras-kras-nras-wild-type-metastatic-colorectal-cancer/ 2021-03-05T07:51:27+00:00 https://infocrc.it/wp-content/uploads/2021/03/4.jpg https://infocrc.it/subgroup-analyses-of-patients-pts-with-microsatellite-instability-high-mismatch-repair-deficient-msi-h-dmmr-metastatic-colorectal-cancer-mcrc-treated-with-nivolumab-nivo-plus-low-dose-ipilimu/ 2021-03-05T07:54:26+00:00 https://infocrc.it/wp-content/uploads/2021/03/1.jpg https://infocrc.it/keynote-177-phase-iii-randomized-study-of-pembrolizumab-versus-chemotherapy-for-microsatellite-instability-high-advanced-colorectal-cancer/ 2021-03-05T07:56:03+00:00 https://infocrc.it/wp-content/uploads/2021/03/2.jpg https://infocrc.it/risposta-metabolica-con-encorafenib-piu-cetuximab-in-un-caso-di-mcrc-braf-v600e-mutato/ 2021-03-05T16:03:53+00:00 https://infocrc.it/wp-content/uploads/2021/03/cliniccase.png https://infocrc.it/azienda-ospedaliero-universitaria-pisana-ospedale-santa-chiara/ 2021-07-02T13:56:36+00:00 https://infocrc.it/wp-content/uploads/2021/03/aou_pisana-stchiara.jpg https://infocrc.it/customisation-of-therapeutic-strategy-in-metastatic-colorectal-cancer-by-use-of-liquid-biopsies-final-results-of-an-observational-study/ 2021-07-21T15:32:12+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1175205281.jpg https://infocrc.it/doublet-regimen-plus-anti-vascular-endothelial-growth-factor-drug-regimen-after-progression-to-first-line-folfoxiri-and-bevacizumab-in-metastatic-colorectal-cancer/ 2021-07-21T15:32:14+00:00 https://infocrc.it/wp-content/uploads/2021/03/1.jpg https://infocrc.it/the-importance-of-maintenance-chemotherapy-in-the-first-and-second-lines-of-treatment-of-metastatic-colorectal-cancer/ 2021-07-21T15:32:16+00:00 https://infocrc.it/wp-content/uploads/2021/03/2.jpg https://infocrc.it/baseline-characteristics-of-patients-enrolled-in-the-capstan-study-a-european-retrospective-study-in-brafv600e-mutant-metastatic-colorectal-cancer-patients/ 2021-07-21T15:32:18+00:00 https://infocrc.it/wp-content/uploads/2021/03/3.jpg https://infocrc.it/encorafenib-and-cetuximab-in-patients-with-metastatic-braf-v600e-mutated-colorectal-carcinoma-a-multi-centric-multi-national-prospective-longitudinal-non-interventional-study-in-germany-and-aus/ 2021-07-21T15:32:19+00:00 https://infocrc.it/wp-content/uploads/2021/03/4.jpg https://infocrc.it/reduced-dose-of-doublet-chemotherapy-combined-with-anti-egfr-antibodies-as-treatment-option-in-vulnerable-older-patients-with-metastatic-colorectal-cancer-a-retrospective-cohort-study/ 2021-07-21T15:32:21+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1175205281.jpg https://infocrc.it/concomitant-ras-and-braf-mutations-impact-on-overall-survival-and-progression-free-survival-in-metastatic-colorectal-cancer-patients/ 2021-07-21T15:32:23+00:00 https://infocrc.it/wp-content/uploads/2021/03/1.jpg https://infocrc.it/integrated-analysis-of-cell-free-dna-braf-mutant-allele-fraction-and-whole-exome-sequencing-in-brafv600e-metastatic-colorectal-cancer-treated-with-braf-antiefgr-mek-inhibitors/ 2021-07-21T15:32:24+00:00 https://infocrc.it/wp-content/uploads/2021/03/3.jpg https://infocrc.it/anchor-crc-results-from-a-single-arm-phase-2-study-of-encorafenib-binimetinib-plus-cetuximab-in-previously-untreated-braf-v600e-mutant-metastatic-colorectal-cancer/ 2021-07-21T15:32:24+00:00 https://infocrc.it/wp-content/uploads/2021/03/4.jpg https://infocrc.it/effect-of-prior-bevacizumab-treatment-in-braf-v600e-mutant-metastatic-colorectal-cancer-overall-survival-with-encorafenib-cetuximab-binimetinib-in-beacon-crc/ 2021-07-21T15:32:24+00:00 https://infocrc.it/wp-content/uploads/2021/03/2.jpg https://infocrc.it/unmet-needs-nel-mcrc-update-da-esmo-gi/ 2021-07-21T16:14:33+00:00 https://infocrc.it/wp-content/uploads/2021/07/crc-pdv0721.png https://infocrc.it/istituto-nazionale-tumori-irccs-fondazione-pascale-di-napoli/ 2021-07-22T10:29:26+00:00 https://infocrc.it/wp-content/uploads/2021/07/centro-0721.jpg https://infocrc.it/regime-a-doppio-target-in-un-caso-di-mcrc-con-mutazione-di-braf/ 2021-07-22T12:31:25+00:00 https://infocrc.it/wp-content/uploads/2021/07/cc-0721.jpg https://infocrc.it/instabilita-microsatellitare-e-mutazione-di-braf-tra-i-temi-caldi-dellasco-gi/ 2021-12-22T09:00:03+00:00 https://infocrc.it/wp-content/uploads/2021/03/infocrc-pdv-1.jpg https://infocrc.it/carcinoma-del-colon-retto-braf-mutato-nuove-evidenze-dallo-studio-beacon/ 2021-12-22T13:37:50+00:00 https://infocrc.it/wp-content/uploads/2021/12/zaniboni.jpg https://infocrc.it/aspetti-nutrizionali-nel-carcinoma-del-colon-retto-limportanza-del-counseling/ 2021-12-22T13:52:34+00:00 https://infocrc.it/wp-content/uploads/2021/12/ip-1221.jpg https://infocrc.it/cliniciansattitude-to-doublet-plus-anti-egfr-versus-triplet-plus-bevacizumab-as-first-line-treatment-in-patients-with-leftsided-ras-and-braf-wild-type-metastatic-colorectal-cancer-a-multic/ 2021-12-22T14:02:32+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1175839437.jpg https://infocrc.it/potential-emerging-role-of-liquid-biopsy-in-clinical-practice-in-metastatic-colorectal-cancer-treatment/ 2021-12-22T14:02:45+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1172127508.jpg https://infocrc.it/circulating-tumour-dna-guided-retreatment-with-anti-egfr-based-therapy-in-ras-wild-type-metastatic-colorectal-cancer-evidence-from-the-clinical-practice/ 2021-12-22T14:02:53+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1159789736.jpg https://infocrc.it/risposta-di-lunga-durata-con-trattamento-a-doppio-target-in-paziente-con-mcrc-braf-v600e-mutato-e-instabilita-microsatellitare/ 2021-12-22T14:19:17+00:00 https://infocrc.it/wp-content/uploads/2021/12/cc-1221.png https://infocrc.it/encorafenib-plus-cetuximab-with-or-without-binimetinib-in-brafv600e-mutated-metastatic-colorectal-cancer-patients-an-italian-multicenter-real-life-experience/ 2021-12-22T16:14:17+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1175839437.jpg https://infocrc.it/the-role-of-site-of-metastatic-resection-mr-in-metastatic-colorectal-cancer-patients-a-monoinstitutional-cohort-study/ 2021-12-22T16:14:52+00:00 https://infocrc.it/wp-content/uploads/2021/03/1.jpg https://infocrc.it/cd44-expression-in-metastatic-colorectal-cancer-new-prognostic-biomarker/ 2021-12-22T16:16:13+00:00 https://infocrc.it/wp-content/uploads/2021/03/3.jpg https://infocrc.it/post-induction-management-in-left-sided-ras-and-braf-wild-type-metastatic-colorectal-cancer-patients-treated-with-first-line-anti-egfr-based-doublet-regimens-a-multicenter-real-life/ 2021-12-22T16:19:03+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1174341081.jpg https://infocrc.it/azienda-ospedaliero-universitaria-di-modena/ 2021-12-27T15:04:48+00:00 https://infocrc.it/wp-content/uploads/2021/12/ic-1221p.jpg https://infocrc.it/alterazioni-molecolari-nel-tumore-del-colon-retto-nuovi-approcci-terapeutici/ 2022-02-23T10:26:41+00:00 https://infocrc.it/wp-content/uploads/2021/07/podcast-1.jpg https://infocrc.it/encorafenib-cetuximab-and-cytotoxic-chemotherapy-combinations-in-brafv600e-crc-murine-models/ 2022-02-24T09:14:10+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1159789736.jpg https://infocrc.it/prognostic-effect-of-ras-braf-mutations-in-patients-with-metastatic-colorectal-cancer/ 2022-02-24T09:14:28+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1175839437.jpg https://infocrc.it/comprehensive-landscape-of-braf-variant-classes-clonalities-and-comutations-in-metastatic-colorectal-cancer-using-ctdna-profiling/ 2022-02-24T09:16:18+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1173705036.jpg https://infocrc.it/wjog13219g-triplet-versus-doublet-in-patients-with-previously-untreated-brafv600e-mutant-metastatic-colorectal-cancer-a-multi-institutional-real-world-data-analysis-bracelet-study/ 2022-02-24T09:17:52+00:00 https://infocrc.it/wp-content/uploads/2021/03/2.jpg https://infocrc.it/real-world-data-analysis-of-antiangiogenic-targeted-treatments-in-second-line-following-anti-egfr-antibodies-and-folfox-in-first-line-for-patients-with-metastatic-colorectal-cancer/ 2022-02-24T09:22:07+00:00 https://infocrc.it/wp-content/uploads/2021/03/3.jpg https://infocrc.it/options-beyond-braf-targeted-therapy-in-second-line-treatment-of-patients-with-brafv600e-mutant-metastatic-colorectal-cancer/ 2022-02-24T09:23:01+00:00 https://infocrc.it/wp-content/uploads/2021/03/4.jpg https://infocrc.it/breakwater-safety-lead-in-sli-encorafenib-cetuximab-%c2%b1-chemotherapy-for-first-line-treatment-of-braf-v600e-mutant-metastatic-colorectal-cancer/ 2022-02-24T09:25:04+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1172127336.jpg https://infocrc.it/caratterizzazione-biomolecolare-nel-mcrc-a-che-punto-siamo/ 2022-02-24T16:23:25+00:00 https://infocrc.it/wp-content/uploads/2022/02/iStock-1348189173.jpg https://infocrc.it/asco-gi-insight-dagli-studi-beacon-e-breakwater/ 2022-02-24T16:31:14+00:00 https://infocrc.it/wp-content/uploads/2022/02/LonardiYT.jpg https://infocrc.it/crc-braf-mutato-approccio-integrato-e-outcome-di-os/ 2022-02-25T07:41:25+00:00 https://infocrc.it/wp-content/uploads/2022/02/img1.jpg https://infocrc.it/phase-i-ii-trial-of-encorafenib-cetuximab-and-nivolumab-in-patients-with-microsatellite-stable-brafv600e-metastatic-colorectal-cancer/ 2022-02-25T07:44:24+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1175205281.jpg https://infocrc.it/safety-and-efficacy-of-encorafenib-binimetinib-plus-cetuximab-for-braf-v600e-mutant-metastatic-colorectal-cancer-results-of-a-prospective-study-as-an-expanded-access-program/ 2022-02-25T07:45:28+00:00 https://infocrc.it/wp-content/uploads/2021/07/iStock-1186804211.png https://infocrc.it/molecular-correlates-of-clinical-benefit-in-previously-treated-patients-with-braf-v600emutant-metastatic-colorectal-cancer-from-the-beacon-study/ 2022-02-25T07:46:35+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1175839437.jpg https://infocrc.it/evaluation-of-baseline-braf-v600e-mutation-in-circulating-tumor-dna-and-efficacy-response-from-the-beacon-study/ 2022-02-25T07:47:18+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1172127336.jpg https://infocrc.it/adenocarcinoma-del-colon-metastatico-con-mutazione-di-braf-v600e-e-msi-h/ 2022-07-12T11:06:44+00:00 https://infocrc.it/wp-content/uploads/2022/07/Caso-clinico-Pretta.jpg https://infocrc.it/breakwater-safety-lead-in-encorafenib-cetuximab-%c2%b1-chemotherapy-for-first-line-treatment-of-braf-v600e-mutant-metastatic-colorectal-cancer/ 2022-07-13T08:32:40+00:00 https://infocrc.it/wp-content/uploads/2021/03/infoCRC-signup.jpg https://infocrc.it/evaluation-of-baseline-braf-v600e-mutation-in-circulating-tumor-dna-and-efficacy-response-from-the-beacon-study-2/ 2022-07-13T08:37:17+00:00 https://infocrc.it/wp-content/uploads/2021/03/4.jpg https://infocrc.it/safety-and-efficacy-of-encorafenib-binimetinib-plus-cetuximab-for-braf-v600e-mutant-metastatic-colorectal-cancer-results-of-a-prospective-study-as-an-expanded-access-program-2/ 2022-07-13T08:43:00+00:00 https://infocrc.it/wp-content/uploads/2021/03/3.jpg https://infocrc.it/phase-i-ii-trial-of-encorafenib-cetuximab-and-nivolumab-in-patients-with-microsatellite-stable-brafv600e-metastatic-colorectal-cancer-2/ 2022-07-13T08:49:05+00:00 https://infocrc.it/wp-content/uploads/2021/03/2.jpg https://infocrc.it/comprehensive-landscape-of-braf-variant-classes-clonalities-and-comutations-in-metastatic-colorectal-cancer-using-ctdna-profiling-2/ 2022-07-13T08:52:54+00:00 https://infocrc.it/wp-content/uploads/2021/03/1.jpg https://infocrc.it/prognostic-effect-of-ras-braf-mutations-in-patients-with-metastatic-colorectal-cancer-2/ 2022-07-13T08:56:49+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1159789736.jpg https://infocrc.it/encorafenib-cetuximab-and-cytotoxic-chemotherapy-combinations-in-brafv600e-crc-murine-models-2/ 2022-07-13T10:05:49+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1175839437.jpg https://infocrc.it/wjog13219g-triplet-versus-doublet-in-patients-with-previously-untreated-brafv600e-mutant-metastatic-colorectal-cancer-a-multi-institutional-real-world-data-analysis-bracelet-study-2/ 2022-07-13T10:16:33+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1173705036.jpg https://infocrc.it/real-world-data-analysis-of-antiangiogenic-targeted-treatments-in-second-line-following-anti-egfr-antibodies-and-folfox-in-first-line-for-patients-with-metastatic-colorectal-cancer-2/ 2022-07-13T11:12:04+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1174341081.jpg https://infocrc.it/options-beyond-braf-targeted-therapy-in-second-line-treatment-of-patients-with-brafv600e-mutant-metastatic-colorectal-cancer-2/ 2022-07-13T11:17:05+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1172127336.jpg https://infocrc.it/association-of-braf-v600e-mutation-with-survival-in-patients-with-metastatic-mismatch-repair-deficient-colorectal-cancer/ 2022-07-13T12:27:53+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1172127336.jpg https://infocrc.it/encorafenib-and-cetuximab-in-patients-with-metastatic-braf-v600e-mutated-colorectal-cancer-update-on-the-first-real-world-study-in-germany-and-austria-bering-crc/ 2022-07-13T13:01:39+00:00 https://infocrc.it/wp-content/uploads/2021/07/iStock-1186804211.png https://infocrc.it/fondazione-policlinico-universitario-campus-bio-medico-roma/ 2022-07-13T13:24:03+00:00 https://infocrc.it/wp-content/uploads/2022/07/Campus-Biomedico-small.jpg https://infocrc.it/mcrc-braf-mutato-da-esmo-gi-nuovi-dati-di-real-life/ 2022-07-13T14:06:22+00:00 https://infocrc.it/wp-content/uploads/2022/07/Cremolini.jpg https://infocrc.it/the-role-of-concomitant-ras-and-braf-mutations-in-influencing-clinical-outcome-during-braf-targeted-treatment-for-metastatic-colorectal-cancer/ 2022-10-05T10:55:04+00:00 https://infocrc.it/wp-content/uploads/2021/07/iStock-1186804211.png https://infocrc.it/prognostic-value-of-lynch-syndrome-brafv600e-and-ras-mutation-status-in-dmmr-msi-h-metastatic-colorectal-cancer-in-a-pooled-analysis-of-the-national-dutch-and-french-cohorts/ 2022-10-05T11:00:11+00:00 https://infocrc.it/wp-content/uploads/2021/03/infoCRC-signup.jpg https://infocrc.it/prospective-evaluation-of-emergent-ras-and-braf-mutations-in-pre-treated-metastatic-colorectal-cancer-patients-candidate-to-anti-egfr-re-treatment-preliminary-findings-from-the-parere-study/ 2022-10-05T11:11:43+00:00 https://infocrc.it/wp-content/uploads/2021/03/2.jpg https://infocrc.it/characteristics-and-survival-of-metastatic-colorectal-cancer-patients-receiving-local-treatment-with-deficient-mismatch-repair-versus-proficient-mismatch-repair/ 2022-10-05T11:15:35+00:00 https://infocrc.it/wp-content/uploads/2021/03/1.jpg https://infocrc.it/microsatellite-instability-testing-practices-in-colorectal-cancer-patients-in-europe-and-asia/ 2022-10-05T14:00:09+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1174341081.jpg https://infocrc.it/liquid-biopsy-detects-early-molecular-response-and-predicts-benefit-to-first-line-chemotherapy-plus-cetuximab-in-metastatic-colorectal-cancer-platform-b-study/ 2022-10-05T14:10:06+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1159789736.jpg https://infocrc.it/impact-of-age-on-treatment-strategies-in-ras-braf-wild-type-metastatic-colorectal-cancer-a-prespecified-subgroup-analysis-of-the-gercor-prodige-strategic-1-phase-iii-study/ 2022-10-05T14:15:44+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1173705036.jpg https://infocrc.it/adenocarcinoma-del-retto-con-mutazione-di-braf-v600e/ 2022-10-05T14:57:22+00:00 https://infocrc.it/wp-content/uploads/2022/10/fenocchio_cover.jpg https://infocrc.it/breakwater-safety-lead-in-encorafenib-cetuximab-chemotherapy-for-brafv600e-metastatic-colorectal-cancer/ 2022-10-06T07:59:44+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1172127336.jpg https://infocrc.it/esmo-2022-importanti-update-dagli-studi-beacon-e-breakwater/ 2022-10-06T08:24:54+00:00 https://infocrc.it/wp-content/uploads/2022/10/MartinelliYT.jpg https://infocrc.it/ruolo-della-terapia-target-nel-trattamento-di-un-paziente-con-carcinosi-peritoneale-da-adenocarcinoma-del-colon-brafv600e-mutato/ 2022-11-21T10:44:14+00:00 https://infocrc.it/wp-content/uploads/2022/10/iStock-1137059077.jpg https://infocrc.it/combinazione-chemo-free-una-storia-nuova-nel-trattamento-del-mcrc/ 2022-11-21T11:29:35+00:00 https://infocrc.it/wp-content/uploads/2022/11/PintoYT.jpg https://infocrc.it/mcrc-braf-mutato-stato-dellartee-prospettive-future/ 2022-11-21T13:53:31+00:00 https://infocrc.it/wp-content/uploads/2022/11/PientrantonioYT.jpg https://infocrc.it/egfr-based-induction-therapy-in-patients-with-ras-wild-type-mcrc/ 2022-11-21T14:09:33+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1172127508.jpg https://infocrc.it/mcrc-patients-treated-with-upfront-chemotherapy-bevacizumab-within-tribe-and-tribe2-studies-a-focus-on-primary-tumor-resection/ 2022-11-21T14:10:25+00:00 https://infocrc.it/wp-content/uploads/2021/03/1.jpg https://infocrc.it/prospective-evaluation-of-emergent-ras-and-braf-mutations-in-pre-trated-mcrc-patients-candidate-to-anti-egfr-retreatment-preliminary-findings-from-the-parere-study/ 2022-11-21T14:10:55+00:00 https://infocrc.it/wp-content/uploads/2021/03/2.jpg https://infocrc.it/folfoxiri-bevacizumab-with-nivolumab-as-first-line-therapy-in-mcrc-with-ras-braf-mutations-regardeless-of-microsatellite-status-results-of-nivacor-trial/ 2022-11-21T14:11:14+00:00 https://infocrc.it/wp-content/uploads/2021/03/3.jpg https://infocrc.it/modified-folfoxiri-plus-panitumumab-vs-mfolfox6-pan-as-initial-treatment-of-unresactable-ras-braf-wild-type-mcrc-results-of-the-triplete-study-by-gono/ 2022-11-21T14:11:28+00:00 https://infocrc.it/wp-content/uploads/2021/03/4.jpg https://infocrc.it/concomitant-ras-and-braf-mutations-in-mcrc-patients-as-prognostic-and-predictive-factor/ 2022-11-21T14:12:21+00:00 https://infocrc.it/wp-content/uploads/2021/07/iStock-1186804211.png https://infocrc.it/prognostic-value-of-a-risk-score-system-for-metastatic-mucinous-crc-an-exploratory-study/ 2022-11-21T14:13:30+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1175839437.jpg https://infocrc.it/the-role-of-the-pre-treatment-inflammatory-biomarkers-in-the-prediction-of-the-early-response-to-panitumumabin-mcrc/ 2022-11-21T14:16:09+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1159789736.jpg https://infocrc.it/genomic-mechanisms-of-acquired-resistance-of-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer-treated-in-the-beacon-study/ 2022-11-21T14:19:06+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1173705036.jpg https://infocrc.it/impact-of-anti-egfr-therapies-on-her2-positive-metastatic-colorectal-cancer-her2-mcrc-a-systematic-literature-review-and-meta-analysis-of-clinical-outcomes/ 2022-11-21T14:20:01+00:00 https://infocrc.it/wp-content/uploads/2021/03/4.jpg https://infocrc.it/novita-terapeutiche-nel-trattamento-di-crc-e-melanoma-metastatici-con-mutazione-di-braf/ 2022-11-22T10:06:56+00:00 https://infocrc.it/wp-content/uploads/2022/11/beacon.jpg https://infocrc.it/pattern-of-disease-progression-in-braf-v600e-mutant-mcrc-trated-with-encoafenib-and-cetuximab-a-single-institution-analysis/ 2023-02-14T13:39:15+00:00 https://infocrc.it/wp-content/uploads/2021/03/infoCRC-signup.jpg https://infocrc.it/trifluridine-tipiracil-plus-bevacizumab-for-third-line-treatment-of-refractory-mcrc-the-phase-3-randomized-sunlight-study/ 2023-02-14T13:45:08+00:00 https://infocrc.it/wp-content/uploads/2021/07/iStock-1186804211.png https://infocrc.it/breakwater-safety-lead-in-encorafenib-cetuximab-chemotherapy-for-brafv600e-mcrc/ 2023-02-14T13:56:06+00:00 https://infocrc.it/wp-content/uploads/2021/03/4.jpg https://infocrc.it/a-single-arm-phase-ii-study-of-autophagy-modulation-using-hydroxychloroquine-in-addition-to-encorafenib-and-cetuximab-or-panitumumab-in-metastatic-braf-mutated-colorectal-cancer-refractory-to-standar/ 2023-02-14T14:10:54+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1174341081.jpg https://infocrc.it/tridente-trial-a-phase-ii-study-of-rechallenge-with-encorafenib-binimetinib-and-cetuximab-in-patients-with-ras-wild-type-braf-v600e-mutant-mcrc/ 2023-02-14T14:16:12+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1172127508.jpg https://infocrc.it/sequencing-con-immunoterapia-e-target-therapy-in-un-caso-di-presenza-contemporanea-di-msi-i-e-mutazione-di-braf-v600e-2/ 2023-02-14T16:14:51+00:00 https://infocrc.it/wp-content/uploads/2023/02/iStock-1289182722-e1676390900636.jpg https://infocrc.it/randomized-phase-ii-trial-of-encorafenib-and-cetuximab-with-or-without-nivolumab-for-patients-with-previously-treated-microsatellite-stable-brafv600e-metastatic-and-or-unresectable-colorectal-cancer/ 2023-02-15T09:21:10+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1159789736.jpg https://infocrc.it/seamark-randomized-phase-2-study-of-pembrolizumab-encorafenib-cetuximab-vs-pembrolizumab-alone-for-first-line-treatment-of-braf-v600e-mutant-msi-h-mismatch-repair-deficient-mcrc/ 2023-02-15T09:32:53+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1174341081.jpg https://infocrc.it/azienda-ospedaliero-universitaria-delle-marche-cancer-center/ 2023-02-15T11:39:14+00:00 https://infocrc.it/wp-content/uploads/2023/02/Riuniti.jpg https://infocrc.it/effectiveness-and-safety-of-encorafenib-cetuximab-in-brafv600e-metastatic-colorectal-cancer-confidence-study/ 2023-02-15T13:06:04+00:00 https://infocrc.it/wp-content/uploads/2021/03/1.jpg https://infocrc.it/microsatellite-instability-mismatch-repair-and-tmb-as-predictive-biomarkers-for-immune-checkpoint-inhibitor-effectiveness-in-real-world-patients-with-mcrc/ 2023-02-15T13:10:48+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1175205281.jpg https://infocrc.it/nuove-linee-guida-per-il-trattamento-del-tumore-del-colon-retto/ 2023-02-15T13:21:15+00:00 https://infocrc.it/wp-content/uploads/2023/02/iStock-1256622909.jpg https://infocrc.it/results-from-a-phase-1a-1b-study-of-botensilimab-a-novel-innate-adaptive-immune-activator-plus-balstilimab-in-metastatic-heavily-pretreated-mss-crc/ 2023-02-15T13:25:15+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1173705036.jpg https://infocrc.it/disease-characteristics-and-clinical-practice-of-braf-v600e-mutant-metastatic-colorectal-cancer-treatment-baseline-analysis-of-patients-enrolled-in-the-bering-crc-study/ 2023-02-15T13:26:08+00:00 https://infocrc.it/wp-content/uploads/2021/03/infoCRC-signup.jpg https://infocrc.it/mcrc-da-asco-gi-nuovi-evidenze-e-importanti-conferme/ 2023-02-15T15:09:47+00:00 https://infocrc.it/wp-content/uploads/2023/02/salvatore.jpg https://infocrc.it/qualita-di-vita-al-centro-della-presa-in-carico-del-paziente-con-crc/ 2023-03-10T14:49:44+00:00 https://infocrc.it/wp-content/uploads/2022/10/mic-podcast-1022-e1665045070483.jpg https://infocrc.it/ospedale-vito-fazzi-di-lecce/ 2023-07-10T10:10:12+00:00 https://infocrc.it/wp-content/uploads/2023/07/Vito-fazzi.jpg https://infocrc.it/mutazione-di-braf-e-instabilita-microsatellitare-nel-mcrc-overview-da-esmo-gi/ 2023-07-10T12:21:23+00:00 https://infocrc.it/wp-content/uploads/2023/07/CiardielloYT.jpg https://infocrc.it/a-novel-concomitant-nras-and-braf-mutation-in-metastatic-colorectal-cancer/ 2023-07-10T12:26:48+00:00 https://infocrc.it/wp-content/uploads/2021/03/4.jpg https://infocrc.it/current-practices-in-mcrc-results-from-the-real-world-screening-and-consensus-based-on-practices-and-evidence-scope-program-in-gastrointestinal-cancers/ 2023-07-10T12:27:25+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1175205281.jpg https://infocrc.it/braf-mutant-metastatic-colon-cancer-expect-the-unexpected-a-single-centre-study/ 2023-07-10T12:28:02+00:00 https://infocrc.it/wp-content/uploads/2021/03/2.jpg https://infocrc.it/unmet-needs-of-patients-during-colorectal-cancer-care-and-treatment-a-qualitative-study-through-an-online-patient-community/ 2023-07-10T12:28:11+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1159789736.jpg https://infocrc.it/prognostic-impact-of-depth-of-response-and-early-tumour-shrinkage-in-patients-with-brafv600e-mutated-mcrc-receiving-targeted-therapy-as-second-line-treatment/ 2023-07-10T12:28:47+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1175839437.jpg https://infocrc.it/predictive-impact-of-rnf43-mutation-in-patients-with-pmmr-mss-braf-v600e-mutated-mcrc-treated-with-target-therapy-or-chemotherapy/ 2023-07-10T12:47:13+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1172127336.jpg https://infocrc.it/the-effect-of-ras-braf-mutation-status-on-survival-and-treatment-efficacy-in-vulnerable-older-patients-with-metastatic-colorectal-cancer-a-post-hoc-exploratory-analysis-of-the-randomized-nor/ 2023-07-10T12:53:53+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1173705036.jpg https://infocrc.it/clinical-outcomes-of-encorafenib-binimetinib-and-cetuximab-for-pretreated-braf-v600e-mutant-mcrc-in-the-beacon-eap-follow-up-study/ 2023-07-10T12:55:58+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1172127508.jpg https://infocrc.it/randomized-phase-ii-trial-of-encorafenib-and-cetuximab-with-or-without-nivolumab-for-patients-with-previously-treated-microsatellite-stable-brafv600e-metastatic-and-or-unresectable-colorectal-cancer-2/ 2023-07-10T12:56:28+00:00 https://infocrc.it/wp-content/uploads/2021/03/3.jpg https://infocrc.it/novel-data-visualization-and-unsupervised-machine-learning-techniques-to-support-optimal-management-of-toxicity-profiles-of-encorafenib-plus-cetuximab-in-patients-with-brafv600e-mutant-mcrc/ 2023-07-10T12:57:13+00:00 https://infocrc.it/wp-content/uploads/2021/03/infoCRC-signup.jpg https://infocrc.it/crc-braf-v600e-mutato-trattamento-beyond-progression-e-integrazione-con-tecniche-locoregionali/ 2023-07-10T13:45:51+00:00 https://infocrc.it/wp-content/uploads/2023/07/cover_pastorino.jpg https://infocrc.it/retrospective-analysis-of-management-of-braf-v600e-mutated-colorectal-cancer-in-a-single-institution/ 2023-07-11T09:23:06+00:00 https://infocrc.it/wp-content/uploads/2021/03/1.jpg https://infocrc.it/qualita-di-vita-nel-tumore-del-colon-retto-lo-stato-dellarte/ 2023-07-11T10:05:33+00:00 https://infocrc.it/wp-content/uploads/2023/07/qualita-di-vita-del-colon.jpg https://infocrc.it/clinical-characteristics-efficacy-and-safety-in-patients-receiving-second-or-third-line-encorafenib-plus-cetuximab-vs-control-for-mcrc-beacon-crc-post-hoc-analysis/ 2023-07-12T06:45:18+00:00 https://infocrc.it/wp-content/uploads/2021/07/iStock-1186804211.png https://infocrc.it/mcrc-da-esmo-2023-strategie-a-bersaglio-molecolare-e-conferme-di-real-world/ 2023-10-30T10:18:28+00:00 https://infocrc.it/wp-content/uploads/2023/10/cremolini.jpg https://infocrc.it/time-to-recurrence-and-its-relation-to-survival-after-recurrence-in-patients-resected-for-stage-iii-colon-cancer/ 2023-10-30T11:14:26+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1174341081.jpg https://infocrc.it/sotorasib-plus-panitumumab-versus-standard-of-care-for-chemorefractory-kras-g12c-mutated-mcrc-codebreak-300-phase-iii-study/ 2023-10-30T13:22:19+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1175839437.jpg https://infocrc.it/circulating-tumor-dna-dynamics-and-clinical-outcome-in-mcrcpatients-undergoing-front-line-chemotherapy/ 2023-10-30T13:23:13+00:00 https://infocrc.it/wp-content/uploads/2021/03/3.jpg https://infocrc.it/first-line-systemic-treatment-in-patients-with-initially-unresectable-colorectal-cancer-liver-metastases-crlm-overall-survival-of-the-phase-iii-cairo5-study-of-the-dutch-colorectal-cancer-group/ 2023-10-30T13:28:29+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1159789736.jpg https://infocrc.it/efficacy-and-safety-of-the-combination-of-encorafenib-and-cetuximab-in-patients-with-braf-v600e-mutated-metastatic-colorectal-cancer-an-ageo-real-world-multicentre-study/ 2023-10-30T13:42:33+00:00 https://infocrc.it/wp-content/uploads/2021/03/infoCRC-signup.jpg https://infocrc.it/pembrolizumab-versus-chemotherapy-in-microsatellite-instability-high-mismatch-repair-deficient-mcrc-5-year-follow-up-of-the-randomized-phase-iii-keynote-177-study/ 2023-10-30T13:43:42+00:00 https://infocrc.it/wp-content/uploads/2021/03/2.jpg https://infocrc.it/seamark-phase-ii-study-of-first-line-encorafenib-and-cetuximab-plus-pembrolizumab-for-msi-h-dmmr-brafv600e-mutant-mcrc/ 2023-10-30T13:45:24+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1172127508.jpg https://infocrc.it/sequential-treatment-with-regorafeniband-trifluridine-tipiracil-bevacizumab-in-refractory-mcrc-in-community-clinical-practice-in-the-usa/ 2023-12-12T14:28:15+00:00 https://infocrc.it/wp-content/uploads/2021/03/4.jpg https://infocrc.it/the-effect-of-brafv600e-mutation-on-survival-and-treatment-efficacy-in-vulnerable-older-patients-with-mcrc-a-post-hoc-exploratory-analysis-of-the-randomized-nordic9-study/ 2023-12-12T14:28:48+00:00 https://infocrc.it/wp-content/uploads/2020/12/iStock-1173705036.jpg https://infocrc.it/modified-m-folfoxiri-plus-cetuximab-treatment-and-predictive-clinical-factors-for-ras-braf-wild-type-and-left-sided-mcrc-the-deeper-trial/ 2023-12-12T14:29:13+00:00 https://infocrc.it/wp-content/uploads/2021/07/iStock-1186804211.png